Calithera Biosciences, Inc. (CALA): Price and Financial Metrics

Calithera Biosciences, Inc. (CALA): $0.02

0.00 (23.00%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

C

Add CALA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#68 of 380

in industry

CALA Price/Volume Stats

Current price $0.02 52-week high $0.50
Prev. close $0.02 52-week low $0.01
Day low $0.02 Volume 157
Day high $0.02 Avg. volume 1,601
50-day MA $0.03 Dividend yield N/A
200-day MA $0.08 Market Cap 119.85K

CALA Stock Price Chart Interactive Chart >


Calithera Biosciences, Inc. (CALA) Company Bio


Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company was founded in 2010 and is based in South San Francisco, California.


CALA Latest News Stream


Event/Time News Detail
Loading, please wait...

CALA Latest Social Stream


Loading social stream, please wait...

View Full CALA Social Stream

Latest CALA News From Around the Web

Below are the latest news stories about CALITHERA BIOSCIENCES INC that investors may wish to consider to help them evaluate CALA as an investment opportunity.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”). In January 2023, the Company announced its intention to com

Yahoo | May 19, 2023

Biotech company Calithera plans its own death. Will others follow?

The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.

Yahoo | January 10, 2023

Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution

Calithera Biosciences Inc (NASDAQ: CALA) announced that its Board of Directors has determined that it is in the best interests of its shareholders to dissolve the company and liquidate its assets. To reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. The company intends to call its shareholders for a special meeting in the

Yahoo | January 9, 2023

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all

Yahoo | January 9, 2023

Read More 'CALA' Stories Here

CALA Price Returns

1-mo -20.32%
3-mo -33.33%
6-mo -60.00%
1-year -63.64%
3-year -99.96%
5-year -99.99%
YTD -33.33%
2023 -99.08%
2022 -75.50%
2021 -86.45%
2020 -14.01%
2019 42.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!